Tonix Pharmaceuticals to present TONMYA Phase 3 analysis at IASP Pain Congress
TNXP•Tonix Pharmaceuticals will present a Phase 3 TONMYA analysis on October 27, 2026, at the IASP World Congress on Pain in Bangkok. The analysis indicates reduced fibromyalgia impact on physical symptoms and functional ability.
1. Congress presentation
Tonix Pharmaceuticals will present a Phase 3 analysis of TONMYA at the IASP World Congress on Pain in Bangkok on October 27, 2026. The analysis indicates reduced fibromyalgia impact on physical symptoms and functional ability.
2. Approval and launch
TONMYA received FDA approval for adult fibromyalgia on August 15, 2025, and its U.S. commercial launch followed on November 17, 2025.
